93,458 results match your criteria Targeted Cancer Therapy

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

J Immunother Cancer 2022 Jun;10(6)

Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

Background: Immune checkpoint blockade (ICB) has achieved unprecedented success in treating multiple cancer types. However, clinical benefit remains modest for most patients with solid malignancies due to primary or acquired resistance. Tumor-intrinsic loss of major histocompatibility complex class I (MHC-I) and aberrations in antigen processing machinery (APM) and interferon gamma (IFN-γ) pathways have been shown to play an important role in ICB resistance. Read More

View Article and Full-Text PDF

The deleterious effect of acetaminophen in cancer immunotherapy.

Ann Oncol 2022 Jun 25. Epub 2022 Jun 25.

Department of Medicine, Teermer Center for Targeted Therapy and Center for Melanoma Massachusetts General Hospital Cancer Center; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article and Full-Text PDF

Synthesis of manganese-incorporated polycaplactone-poly (glyceryl methacrylate) theranostic smart hybrid polymersomes for efficient colon adenocarcinoma treatment.

Int J Pharm 2022 Jun 25:121963. Epub 2022 Jun 25.

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

In the current study, a multifunctional nanoscale vesicular system (polymersome) with the ability to accumulate in the site of action, control drug release and integrate diagnostic and therapeutic functions was developed. The theranostic polymersome was engineered as a promising dual-functional nanoplatform, which can be used for tumor therapy and magnetic resonance imaging (MRI). In this regard, the amphiphilic diblock copolymer of poly(ε-caprolactone)-block-poly(glyceryl methacrylate)[(PCL-b-PGMA)] was synthesized by combined ring-opening polymerization (ROP), and reversible addition-fragmentation chain-transfer (RAFT) polymerization techniques followed by hydrolysis of the pendant oxiran rings to hydroxyl groups. Read More

View Article and Full-Text PDF

Lung adenocarcinoma harboring triple rare EGFR exon18 mutations rapidly developed resistance to multiple therapies.

Chemotherapy 2022 Jun 28. Epub 2022 Jun 28.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths worldwide. Its medical significance has spurred broad investigations into its treatment and prognosis. Shortly after the oncogenic driver mutations were identified, targeted therapies for NSCLC developed rapidly, including the discovery of tyrosine kinase inhibitors (TKIs). Read More

View Article and Full-Text PDF

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

J Clin Oncol 2022 Jun 28:JCO2102772. Epub 2022 Jun 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients.

Methods: Patients with a primary tumor of > 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0) were randomly assigned 1:1 to atezolizumab/placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel, and PH. Read More

View Article and Full-Text PDF

Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.

Blood 2022 Jun 28. Epub 2022 Jun 28.

Mayo Clinic Florida, Jacksonville, Florida, United States.

Children's Oncology Group trial AHOD0431 reduced systemic therapy and used response-adapted involved-field radiotherapy (IFRT) in early-stage pediatric classical Hodgkin lymphoma. We investigated the impact of PET response after 1 cycle (PET1) and IFRT on outcomes and relapse pattern. Patients on AHOD 0431 underwent PET1 response assessment after AVPC (doxorubicin, vincristine, prednisone, and cyclophosphamide). Read More

View Article and Full-Text PDF

Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy.

Asian Pac J Cancer Prev 2022 Jun 1;23(6):1993-2000. Epub 2022 Jun 1.

Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Background And Aim: Prostate cancer is the second most common cancer among men that has affected their quality of life. This study aimed to find prostate tissue-specific genes using bioinformatics methods to specifically target prostate cells in case of metastasis to other tissues.

Materials And Methods: In this study, after finding a specific gene (MSMB)  that is highly expressed in cancer, the optimal promoter region of this gene was isolated and inserted in an expression vector. Read More

View Article and Full-Text PDF

Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing normal hematopoietic stem cells.

J Clin Invest 2022 Jun 28. Epub 2022 Jun 28.

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States of America.

Targeted protein degradation is a rapidly advancing and expanding therapeutic approach. Drugs that degrade GSPT1 via the CRL4CRBN ubiquitin ligase are a new class of cancer therapy in active clinical development with evidence of activity against acute myeloid leukemia in early phase trials. However, other than activation of the integrated stress response, the downstream effects of GSPT1 degradation leading to cell death are largely undefined, and no murine models are available to study these agents. Read More

View Article and Full-Text PDF

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [Ga]Ga-PSMA-617.

Eur J Nucl Med Mol Imaging 2022 Jun 28. Epub 2022 Jun 28.

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China.

Objective: Hepatocellular carcinoma (HCC) is a malignant tumor associated with high morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate-specific membrane antigens (PSMA) are overexpressed in tumor-associated endothelial cells. Therefore, the aim of this study was to evaluate the performance of [Ga]Ga-PSMA-617 PET imaging on HCC with different animal models, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), and to explore its mechanisms of function. Read More

View Article and Full-Text PDF

Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.

Exp Biol Med (Maywood) 2022 Jun 28:15353702221102872. Epub 2022 Jun 28.

Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.

Despite significant advances in targeted and immune therapy for non-small cell lung cancer (NSCLC), effective therapies for wild-type epidermal growth factor receptor/anaplastic lymphoma kinase () with low expression of programmed death ligand-1 (PD-L1) NSCLC remain elusive. Numerous studies have shown that ferroptosis plays an essential role in antitumor activity. To identify the molecular regulation patterns associated with ferroptosis, 351 NSCLC samples with low-level PD-L1 were extracted from The Cancer Genome Atlas (TCGA) and clustered using the k-means clustering technique. Read More

View Article and Full-Text PDF

Research progress on immunotherapy in triple‑negative breast cancer (Review).

Int J Oncol 2022 Aug 28;61(2). Epub 2022 Jun 28.

Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130012, P.R. China.

Triple‑negative breast cancer (TNBC) is a highly heterogeneous and aggressive malignancy. Due to the absence of estrogen receptors and progesterone receptors and the lack of overexpression of human epidermal growth factor receptor 2, TNBC responds poorly to endocrine and targeted therapies. As a neoadjuvant therapy, chemotherapy is usually the only option for TNBC; however, chemotherapy may induce tumor resistance. Read More

View Article and Full-Text PDF

Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

J Cell Mol Med 2022 Jun 28. Epub 2022 Jun 28.

Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran.

Despite substantial developments in conventional treatments such as surgery, chemotherapy, radiotherapy, endocrine therapy, and molecular-targeted therapy, breast cancer remains the leading cause of cancer mortality in women. Currently, chimeric antigen receptor (CAR)-redirected immune cell therapy has emerged as an innovative immunotherapeutic approach to ameliorate survival rates of breast cancer patients by eliciting cytotoxic activity against cognate tumour-associated antigens expressing tumour cells. As a crucial component of adaptive immunity, T cells and NK cells, as the central innate immune cells, are two types of pivotal candidates for CAR engineering in treating solid malignancies. Read More

View Article and Full-Text PDF

Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.

Cancer Rep (Hoboken) 2022 Jun 27:e1656. Epub 2022 Jun 27.

UA Health Sciences, University of Arizona (UA) Cancer Center, Tucson, Arizona, USA.

Background: Ameloblastoma imposes significant morbidity and high-recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined.

Case: We describe a case of a 40-year-old male with multiply recurrent, locally invasive ameloblastoma of the posterior maxillary ridge. Read More

View Article and Full-Text PDF

Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Exp Hematol Oncol 2022 Jun 27;11(1):39. Epub 2022 Jun 27.

Department of Hematology, Shandong Provincial Hospital, Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, China.

Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of cancer, is considered as a promising therapeutic target against tumors. In chronic lymphocytic leukemia (CLL) cells, metabolic abnormalities mediate alternations in proliferation and survival compared with normal B cells. However, the role of metabolic reprogramming is still under investigation in CLL. Read More

View Article and Full-Text PDF

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).

Clin Transl Oncol 2022 Jun 27. Epub 2022 Jun 27.

Translational Genomics and Targeted Therapies in Solid Tumors, Medical Oncology Department, Hospital Clínic de Barcelona, C/ Villaroel, 170, 08036, Barcelona, Spain.

Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RAS mutations in liquid biopsy (LB). Read More

View Article and Full-Text PDF

Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model.

Sci Rep 2022 Jun 27;12(1):10863. Epub 2022 Jun 27.

Research Laboratory in Human Reproduction, Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Pharmacological approaches offer a non-invasive and promising option for fertility preservation in young female cancer patients undergoing gonadotoxic therapy. The GnRH-agonists are the only clinically available drugs in this indication, but their use and mechanisms of protection are still controversial. Recently, we have investigated new targeted drugs based on microRNA (miRNA) replacement therapy, and have identified the let-7a miRNA as candidate for fertility preservation strategies. Read More

View Article and Full-Text PDF

Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites.

Nat Commun 2022 Jun 27;13(1):3685. Epub 2022 Jun 27.

Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.

CRISPR/Cas9-based genome editing has revolutionized experimental molecular biology and entered the clinical world for targeted gene therapy. Identifying DNA modifications occurring at CRISPR/Cas9 target sites is critical to determine efficiency and safety of editing tools. Here we show that insertions of LINE-1 (L1) retrotransposons can occur frequently at CRISPR/Cas9 editing sites. Read More

View Article and Full-Text PDF

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

Nat Commun 2022 Jun 27;13(1):3671. Epub 2022 Jun 27.

Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.

Few patients with triple negative breast cancer (TNBC) benefit from immune checkpoint inhibitors with complete and durable remissions being quite rare. Oncogenes can regulate tumor immune infiltration, however whether oncogenes dictate diminished response to immunotherapy and whether these effects are reversible remains poorly understood. Here, we report that TNBCs with elevated MYC expression are resistant to immune checkpoint inhibitor therapy. Read More

View Article and Full-Text PDF

Gene Therapy for Pediatric Neurologic Disease.

Hematol Oncol Clin North Am 2022 Jun 24. Epub 2022 Jun 24.

Department of Pediatric Hematology and Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

Pediatric lysosomal and peroxisomal storage disorders, leukodystrophies, and motor neuron diseases can have devastating neurologic manifestations. Despite efforts to exploit cross-correction to treat these monogenic disorders for several decades, definitive treatment has yet to be identified. This review explores recent attempts to transduce autologous hematopoietic stem cells with functional gene or provide therapeutic gene in vivo. Read More

View Article and Full-Text PDF

Analysis of the results of radiotherapy and chemoradiotherapy on the background of immunotherapy of patients with cancer of the oral cavity and oropharynx.

H A Hirna

Klin Onkol 2022 ;35(3):222-231

Background: Advances in medicine, especially in the field of immunology in oncology, contribute to the development of new ways and methods of treating cancer of the oral cavity and oropharynx. Preclinical and clinical studies of cytokine and dendritic cell therapy, blockade of immune checkpoints, T cell uptake, treatment with monoclonal antibodies and peptide vac-cines are performed. Some of these immunotherapeutic drugs are introduced into medical practice. Read More

View Article and Full-Text PDF

Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.

Bull Cancer 2022 May;109(2S):2S4-2S18

Medical Oncology Department, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France.

Immunotherapy (IO) with checkpoint inhibitors with or without anti-angiogenic tyrosine kinase inhibitor (TKI)-based combinations have demonstrated superior efficacy over sunitinib for treatment-naive patients with metastatic clear-cell renal cell carcinoma (mRCC). Four of these combinations (nivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib and pembrolizumab plus lenvatinib) represent new front-line standard-of-care options for mRCC patients, according to the International Metastatic RCC Database Consortium (IMDC) subgroups. Questions over the optimal treatment between IO-IO or IO-TKI combinations for mRCC patients in intermediate/poor IMDC risk groups and the optimal IO-TKI regimen for all IMDC risk groups remain unanswered. Read More

View Article and Full-Text PDF

An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation.

Drug Res (Stuttg) 2022 Jun 27. Epub 2022 Jun 27.

Department of Pharmacy, Goel Institute of Pharmaceutical Sciences, Lucknow, India.

Ovarian cancer is characterized by the establishment of tolerance, the recurrence of disease, as well as a poor prognosis. Gene signatures in ovarian cancer cells enable cancer medicine research, therapy, prevention, & management problematic. Notwithstanding advances in tumor puncture surgery, novel combinations regimens, and abdominal radiation, which can provide outstanding reaction times, the bulk of gynecological tumor patients suffer from side effects & relapse. Read More

View Article and Full-Text PDF

Optimizing antiemetic therapy for children undergoing chemotherapy.

J Pediatr Nurs 2022 Jun 24;66:136-142. Epub 2022 Jun 24.

Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 13123 East 16(th) Avenue, Aurora, CO 80045, United States of America.

Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of most chemotherapy agents. Suboptimal management of CINV impacts quality of life, nutrition, gastrointestinal (GI) integrity, and adherence to chemotherapy treatment plans. This article reviews the principles of CINV management, planning and implementation of antiemetic regimens, and pharmacology of the antiemetics currently available in the United States appropriate for pediatric use. Read More

View Article and Full-Text PDF

Folic acid-mediated [email protected]@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer.

Colloids Surf B Biointerfaces 2022 Jun 17;217:112639. Epub 2022 Jun 17.

Department of Thoracic Surgery, First Affiliated Hospital of Fujian Medical University, 350005 Fuzhou, Fujian, China. Electronic address:

Molecularly targeted drugs are flourishing in the clinical treatment of non-small cell lung cancer (NSCLC). However, the treatment of a single drug (such as Gefitinib (Geb)) had defects such as poor pharmacokinetics, insufficient drug delivery, and considerable toxic side effects, which greatly affect its therapeutic efficacy against NSCLC. To solve these issues, this study developed a new nanocomposite heterogeneous platform ([email protected]@Geb-FA) that combined photothermal therapy and molecular targeted therapy. Read More

View Article and Full-Text PDF

Multiple mediation analysis of racial disparity in breast cancer survival.

Cancer Epidemiol 2022 Jun 24;79:102206. Epub 2022 Jun 24.

Stetson University, Public Health Program, Deland, FL, USA.

Background: Racial (Black vs. White) disparities in breast cancer survival have proven difficult to mitigate. Targeted strategies aimed at the primary factors driving the disparity offer the greatest potential for success. Read More

View Article and Full-Text PDF

Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.

Oral Oncol 2022 Jun 24;132:105982. Epub 2022 Jun 24.

Department of Neuroscience DNS, Otolaryngology Section, University of Padova, Padova, Italy. Electronic address:

Objectives: The interaction between tumor cells and stroma is critical in tumorigenesis, tumor neo-angiogenesis and cancer progression. The aims of this study were to: (i) evaluate the concordance between tumor-stroma ratio (TSR) and microvascular density (MVD) on paired biopsy and surgical specimens of laryngeal carcinoma (LSCC); (ii) investigate the association of TSR with angiogenesis (CD105- and CD31-assessed MVD); (iii) assess the prognostic role of TSR and MVD evaluated on preoperative biopsies and paired surgical specimens.

Methods: TSR, CD105- and CD31-assessed MVD were analyzed in paired biopsies and surgical specimens of 43 consecutive cases. Read More

View Article and Full-Text PDF

Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escape from CD19 CAR T-cell therapy.

Cancer Immunol Res 2022 Jun 27. Epub 2022 Jun 27.

Dana-Farber Cancer Institute, Boston, MA, United States.

Chimeric-antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Read More

View Article and Full-Text PDF

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.

Proc Natl Acad Sci U S A 2022 Jul 27;119(27):e2203820119. Epub 2022 Jun 27.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer with limited meaningful treatment options. NEPC lesions uniquely express delta-like ligand 3 (DLL3) on their cell surface. Taking advantage of DLL3 overexpression, we developed and evaluated lutetium-177 (Lu)-labeled DLL3-targeting antibody SC16 (Lu-DTPA-SC16) as a treatment for NEPC. Read More

View Article and Full-Text PDF

Comparison of the Effectiveness of IgG Antibody versus F(ab') Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy.

Mol Pharm 2022 Jun 27. Epub 2022 Jun 27.

Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States.

Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment modality that utilizes antibody-photoabsorber conjugates (APCs) and selectively kills target cells after irradiation with NIR light. Originally, NIR-PIT was targeted against cancer cell surface antigens, but as it became clear that NIR-PIT induced a strong immune response, an effort was made to target selected immune cell populations in the tumor microenvironment to encourage an even stronger immune response. Thus, CD25-targeted NIR-PIT and cytotoxic T-lymphocyte associated protein 4 (CTLA4)-targeted NIR-PIT were developed to kill regulatory T cells (Tregs) in conjunction with cancer-cell-targeted NIR-PIT, in order to amplify the host immune response. Read More

View Article and Full-Text PDF

Current trends in image-guided chest interventions.

Respirology 2022 Jun 27. Epub 2022 Jun 27.

Institute for Diagnostic and Interventional Radiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.

Interventional radiology (IR) is a rapidly expanding medical subspecialty and refers to a range of image-guided procedural techniques. The image guidance allows real-time visualization and precision placement of a needle, catheter, wire and device to deep body structures through small incisions. Advantages include reduced risks, faster recovery and shorter hospital stays, lower costs and less patient discomfort. Read More

View Article and Full-Text PDF